

# 2022-2026 Brazil Cancer Diagnostics Market Opportunities for Major Tumor Markers-Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

https://marketpublishers.com/r/20EFEFF3C6CEN.html

Date: January 2022

Pages: 0

Price: US\$ 2,500.00 (Single User License)

ID: 20EFEFFF3C6CEN

# **Abstracts**

This new report from LeadingMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years.

The report is available by section, and can be customized to specific information needs and budget.

The report examines emerging trends in the cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of innovative technologies; forecasts volume and sales for major cancer diagnostics tests; profiles leading market players and potential entrants; and suggests alternative market expansion strategies for suppliers.

### Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create



numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant

market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Cancer Diagnostic Tests Analyzed in the Report--over 200 current and emerging assays, including Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines and Immunohistochemical Stains, such as:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

### Instrumentation Review

Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

# Technology Review



Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

# Competitive Assessments

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.



# **Contents**

- I. INTRODUCTION
- **II. MARKET OVERVIEW**
- **III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES**
- IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
- V. ALTERNATIVE MARKET PENETRATION STRATEGIES
- VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
- VII. MAJOR CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS
  - 1. Introduction
  - 2. Cancer Diagnostic Classification
  - 3. ACTH
  - 4. Alpha-Fetoprotein (AFP)
  - 5. Beta-2 Microglobulin
  - 6. CA 15-3/27.29
  - 7. CA 19-9
  - 8. CA-125
  - 9. Calcitonin
  - 10. Carcinoembrionic Antigen (CEA)
  - 11. Estrogen and Progesterone Receptors
  - 12. Ferritin
  - 13. Gastrin
  - 14. Human Chorionic Gonadotropin (HCG)
  - 15. Insulin
  - 16. NSE
  - 17. Occult Blood
  - 18. PAP Smear/HPV
  - 19. Prostatic Acid Phosphatase (PAP)
  - 20. Prostate-Specific Antigen (PSA)
  - 21. Squamous Cell Carcinoma Antigen (SCC)
  - 22. T and B Lymphocytes
  - 23. TdT



- 24. Thyroglobulin
- 25. Tissue Polypeptide Antigen (TPA)
- 26. Biochemical Cancer Diagnostics
- 27. Oncogenes

Abl/abl-bcr

AIB1

BCL-2

BRCA1

**CD44** 

C-fos

C-myb

C-myc

CYP-17

Erb-B

HPC1

N-myc

P40

P51

P53

PIK3CA

PTI-1

Ras

Reg

Sis

Src and others

28. Polypeptide Growth Factors

Basic Fibroblast Growth Factor

Beta-TGF

Cachectin (TNT)

Calmodulin

**ECFR** 

Nerve Growth Factor (NGF)

Epidermal Growth Factor (EGF)

Ornithine Decarboxylase

Transferrin

Transforming Growth Factor-Alpha

- 29. Ectopic Hormones
- 30. Colony Stimulating Factors
- 31. Lymphokines



Alpha-Interferon

**B Cell Growth Factors** 

B Cell Growth Factor (BCGF)

Gamma-Interferon

Interleukin-1 (IL-1)

Macrophage Activating Factor

32. Immunohistochemical Stains

33. Emerging Cancer Diagnostics

N-Acetylglucosamine

Actin

Alpha-Actin

**Antineuronal Antibodies** 

7B2

B72.3

Bax

BCD-F9

BLCA-4

Blood Group Antigens A,B,H

CA

CA 72-4/TAG-72

CA

CA-242

CA-549

CAM

CAR-3

Cathepsin-D

Chromogranin A and B

Cluster 1 Antigen

Cluster-5/5A Antigen

CTA

**CU18** 

**DR-70** 

DU-PAN-2

**Endometrial Bleeding Associated Factor** 

Endostatin

Epithelial Membrane Antigen

Feulgen Hydrolysis

Fibronectin

**FSH** 



(1->3)-L-fucosyltransferase

Gastrin-Releasing Peptide (GRP)

GDCFP-15

Glucagon

Glycoamines

H23

Her-2

Human Carcinoma Antigen

**HPA** 

HSP27

Intermediate Filaments

Cytokeratins/CK18/Cyfra 21-1

Desmin

Gliofibrillary Acid Protein

Neurofilaments

Vimentin

KA

Kinases

**KP16D3** 

LAI

Leukocyte Common Antigen

Lewis Antigens

Lysophosphatidic Acid (LPA)

Ma 695/Ma

MABDF3

MAG

ME1

Minactivin

MN/CA9

**MSA** 

Mucin Cancer Antigen (MCA)

Multiple Tumor Suppressor

Myosin

**NEA-130** 

NMP22

OA-519

**Opiod Peptides** 

P-glycoprotein

Pancreatic Oncofetal Antigen (POA)



Placental Lactogen

PR92

Proliferative Index, Ki-67

Px

RB Inactivation/Deletion

Ret

SCCL

Selectin

Sialic Acid

Sialyl SSEA-1/SLX

**SN10** 

Somatostatin

TA-90

**TABA** 

Tachykinin

**TAG** 

**TPS** 

Troponin

Tubulin

**VCAM** 

**VEGF** 

Villen and others

# **VIII. INSTRUMENTATION REVIEW AND MARKET NEEDS**

# IX. CURRENT AND EMERGING TECHNOLOGIES

- 1. Monoclonal and Polyclonal Antibodies
- 2. Immunoassays
- 3. Molecular Diagnostics
- 4. Chromosome Analysis
  - a. Chronic Myelogenous Leukemia (CML)
  - b. Acute Myeloid Leukemia (AML)
  - c. Acute Lymphoblastic Leukemia (ALL)
  - d. Malignant Lymphomas Lymphoid Malignancies
  - e. Chronic Lymphocytic Leukemia (CLL)
- f. Solid Cancers
- g. Chromosomal Translocation and Oncogenes
- 5. Artificial Intelligence



- 6. Flow Cytometry
- 7. Two Dimensional Gel Electrophoresis (2-DGE)
- 8. Biosensors
- 9. Competing/Complementing Technologies

# X. MARKET SIZE, TEST VOLUME AND SALES FORECASTS

### XI. COMPETITIVE PROFILES

The report provides strategic assessments of over 30 leading cancer diagnostics market players and start-up companies with innovative technologies and products, including:

**Abbott** 

**Affymetrix** 

Beckman Coulter/Danaher

Becton Dickinson

bioMerieux

Bio-Rad

Cepheid

**DiaSorin** 

Eiken Chemical

Elitech Group

Enzo Biochem

**Fujirebio** 

Grifols

Hologic

Leica Biosystems

Ortho-Clinical Diagnostics

PerkinElmer

Qiagen

Roche

Siemens Healthineers

Takara Bio

Thermo Fisher

Wako and others.



# I would like to order

Product name: 2022-2026 Brazil Cancer Diagnostics Market Opportunities for Major Tumor Markers-

Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts,

Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

Product link: https://marketpublishers.com/r/20EFEFFF3C6CEN.html

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/20EFEFFF3C6CEN.html">https://marketpublishers.com/r/20EFEFFF3C6CEN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970